Ceribell Receives FDA Clearance for Brain Activity Analysis Software

Key Facts

1CeriBell received US FDA 510(k) clearance for new software designed to simplify the interpretation of longitudinal brain activity.

CeriBell received US FDA 510(k) clearance for new software designed to simplify the interpretation of longitudinal brain activity. GlobeNewswire reported that the clearance covers quantitative EEG trending and amplitude-integrated EEG analysis software, which aims to help clinicians interpret complex data faster for patients with serious neurological conditions.

CBLL closed at $24.86 on September 29, 2026, with the stock reaching a day high of $24.90 and a low of $24.03. This regulatory milestone for the medical technology company is expected to improve product adoption as it continues to expand its AI-powered EEG platform across acute-care settings.